Details for Patent: 12,521,390
Which drugs does patent 12,521,390 protect, and when does it expire?
Patent 12,521,390 protects SOTYKTU and is included in one NDA.
This patent has forty-eight patent family members in twenty countries.
Summary for Patent: 12,521,390
| Title: | Dosage forms for Tyk2 inhibitors |
| Abstract: | Stable and bioavailable formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropancamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I): BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis. |
| Inventor(s): | Sherif Ibrahim Farag Badawy, Jonathan R. Brown, Candice Y. Choi, Christoph Gesenberg, Vivienne Gray, John Wynne Jones, Umesh Kestur, Balvinder S. Vig, Xiaotian S. Yin, Christopher A. Zordan, Corey Bloom, Ian Yates |
| Assignee: | Bristol Myers Squibb Co |
| Application Number: | US17/639,481 |
|
Patent Claim Types: see list of patent claims | Use; Formulation; Dosage form; |
Drugs Protected by US Patent 12,521,390
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol | SOTYKTU | deucravacitinib | TABLET;ORAL | 214958-001 | Sep 9, 2022 | RX | Yes | Yes | 12,521,390 | ⤷ Start Trial | Y | TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN ADULTS WHO ARE CANDIDATES FOR SYSTEMIC THERAPY OR PHOTOTHERAPY | ⤷ Start Trial | |||
| Bristol | SOTYKTU | deucravacitinib | TABLET;ORAL | 214958-001 | Sep 9, 2022 | RX | Yes | Yes | 12,521,390 | ⤷ Start Trial | Y | TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,521,390
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2020348783 | ⤷ Start Trial | |||
| Australia | 2020349524 | ⤷ Start Trial | |||
| Australia | 2026214007 | ⤷ Start Trial | |||
| Brazil | 112022004216 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
